STA-9090 in Patients With Advanced Hepatocellular Cancer
NCT01665937
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
STA-9090
Sponsor
Massachusetts General Hospital
Collaborators
[object Object]
[object Object]
[object Object]